The Semaglutide reading shelf

Tablet formulation reviews and clinical trials

For the preparation question, I favor opening the SNAC absorption review first. It explains why the tablet is an accomplishment without making its practical conditions disappear. PIONEER 1 and OASIS 1 then put the oral preparation into clinical trials with different populations and purposes.

For the injection, STEP 1 is the weight-management starting point. SELECT enlarged my interest beyond weight; FLOW adds the kidney-disease question. SUSTAIN-6 is especially useful beside the safety review, because the same account needs both the cardiovascular result and the eye signal.

SURMOUNT-5 is the direct comparison with tirzepatide. Its shared trial frame is the reason to read it before comparing averages from different studies.

The animal shelf has its own place

Gabery and colleagues studied semaglutide's appetite-related effects in rodents. Secher and colleagues studied liraglutide in mice, not semaglutide in people. Singh and colleagues examined how appetite-neuron activity depends on time and metabolic state in rodents. The alcohol-intake paper is also preclinical.

I enjoy the explanatory ambition of these papers. They sit beside the human outcomes, with their species and compounds intact. The audited list below retains the full publication details, including the additional tablet and kidney analyses.